Cytosorbents (CTSO) Amortizatization of Intangibles (2010 - 2026)
Cytosorbents (CTSO) posted Amortizatization of Intangibles of $291000.0 for Q1 2026, up 166.74% on a QoQ basis from -$436000.0 in Q4 2025, and up 53.16% year-over-year from $190000.0 in Q1 2025.
Cytosorbents (CTSO) Amortizatization of Intangibles (2010 - 2026) Analysis & Trends
Cytosorbents' Amortizatization of Intangibles history runs 16 years deep, the most recent figure standing at $291000.0 for Q1 2026.
- Quarterly Amortizatization of Intangibles rose 53.16% year-over-year to $291000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $236000.0 (down 25.8% YoY) and the FY2025 annual result came in at $135000.0, down 22.41% from the prior year.
- Amortizatization of Intangibles was $291000.0 for Q1 2026 at Cytosorbents, up from -$436000.0 in the prior quarter.
- Across five years, Amortizatization of Intangibles topped out at $499000.0 in Q3 2025 and bottomed at -$436000.0 in Q4 2025.
- A 5-year average of $83139.1 and a median of $55441.0 in 2022 frame the typical range for Amortizatization of Intangibles.
- Peak annual rise in Amortizatization of Intangibles reached 984.78% in 2025, while the deepest fall reached 1311.11% in 2025.
- Cytosorbents' Amortizatization of Intangibles stood at $55441.0 in 2022, then soared by 617.94% to $398035.0 in 2023, then plunged by 90.96% to $36000.0 in 2024, then tumbled by 1311.11% to -$436000.0 in 2025, then surged by 166.74% to $291000.0 in 2026.
- Business Quant data shows CTSO's Amortizatization of Intangibles at $291000.0 in Q1 2026, -$436000.0 in Q4 2025, and $499000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.32 Bn | 175.02 Bn | 6.27 Bn | - |
| 2 | Stryker | 128.75 Bn | 125.88 Bn | 3.81 Bn | - |
| 3 | Medtronic | 107.83 Bn | 98.61 Bn | 6.41 Bn | - |
| 4 | Boston Scientific | 67.61 Bn | 66.15 Bn | 3.61 Bn | - |
| 5 | Edwards Lifesciences | 48.13 Bn | 44.45 Bn | 1.29 Bn | - |
| 6 | Dexcom | 28.26 Bn | 27.14 Bn | 750.30 Mn | - |
| 7 | GE HealthCare Technologies | 27.78 Bn | 25.50 Bn | 1.98 Bn | - |
| 8 | Smith & Nephew | 26.99 Bn | 26.41 Bn | - | - |
| 9 | Koninklijke Philips | 23.92 Bn | 20.80 Bn | 2.07 Bn | - |
| 10 | Cytosorbents | 23.04 Mn | 18.24 Mn | 6.13 Mn | 291,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 291,000.00 |
| Mar 31, 2026 | 291,000.00 |
| Dec 31, 2025 | -436,000.00 |
| Dec 31, 2025 | -436,000.00 |
| Sep 30, 2025 | 499,000.00 |
| Sep 30, 2025 | 499,000.00 |
| Jun 30, 2025 | -118,000.00 |
| Jun 30, 2025 | -118,000.00 |
| Mar 31, 2025 | 190,000.00 |
| Mar 31, 2025 | 190,000.00 |
| Dec 31, 2024 | 36,000.00 |
| Dec 31, 2024 | 36,000.00 |
| Sep 30, 2024 | 46,000.00 |
| Sep 30, 2024 | 46,000.00 |
| Jun 30, 2024 | 46,073.00 |
| Jun 30, 2024 | 46,073.00 |
| Mar 31, 2024 | 45,927.00 |
| Mar 31, 2024 | 45,927.00 |
| Dec 31, 2023 | 398,035.00 |
| Dec 31, 2023 | 398,035.00 |